SAN FRANCISCO, Sept. 26, 2018 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, today announced that it will participate in the following
investor conferences in October:
- Leerink Partners Roundtable Series: Rare Disease &
Oncology
Natalie Holles,
President and Chief Operating Officer
Format: Fireside Chat
Tuesday, October 2, 2018,
9:30 am ET
New York, New York
- Chardan 2nd Annual Genetic Medicines
Conference
Matthew R.
Patterson, Chief Executive Officer
Panel: Genetic Medicines: Pre-Commercial, Manufacturing &
Regulatory Strategies
Tuesday, October 9, 2018,
12:10 pm ET
Format: Fireside Chat
Tuesday, October 9, 2018,
3:45 pm ET
New York, New York
To access live webcasts of the fireside chats, please visit the
Events & Presentations page within the Investors + Media
section of the Audentes website. Following each conference, a
replay of the live webcast will be available on the Audentes
website for approximately 30 days. There is no webcast
available for the Genetic Medicines: Pre-Commercial, Manufacturing
& Regulatory Strategies panel at the Chardan 2nd Annual Genetic
Medicines Conference.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused
on developing and commercializing innovative gene therapy products
for patients living with serious, life-threatening rare
diseases. We are currently conducting
Phase 1/2 clinical studies of our lead product
candidates, AT132 for the treatment of X-linked myotubular myopathy
(XLMTM), and AT342 for the treatment of Crigler-Najjar
syndrome. We have two additional product candidates in
development, including AT982 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
catecholaminergic polymorphic ventricular tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please
visit www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-participate-in-upcoming-investor-conferences-300718850.html
SOURCE Audentes Therapeutics, Inc.